Domo signs strategic collaboration agreement with AWS for AI solutions
Incannex Healthcare Inc. (NASDAQ:IXHL), a pharmaceutical company, announced today that it has amended its Sales Agreement with A.G.P/Alliance Global Partners (NYSE:GLP) to increase the maximum offering of its common stock. The amendment, effective as of May 20, 2025, allows the company to offer up to an additional $2,514,214 of common stock, par value $0.0001 per share. This is in addition to approximately $16,768,095 worth of shares already sold under the same agreement.
The Sales Agreement, originally dated April 7, 2025, outlines the terms under which Incannex Healthcare Inc. can issue shares via A.G.P/Alliance Global Partners. The recent filing with the Securities and Exchange Commission (SEC) includes an opinion from the law firm Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., regarding the legality of the share issuance and sale.
This development comes as the company, which is listed on the Nasdaq Stock Market LLC, continues to position itself for growth. Incannex Healthcare Inc. is recognized as an emerging growth company and has not elected to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
The company’s SEC filing also includes Exhibit 5.1, which contains the legal opinion from Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., and Exhibit 23.1, which includes the consent of the same law firm. Additionally, Exhibit 104 contains the Cover Page Interactive Data File, embedded within the Inline XBRL document.
The information disclosed in this article is based on a press release statement from Incannex Healthcare Inc. and is intended to inform the public and investors of the company’s financial activities as required by law.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.